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Abstract: The neurotransmitter glutamate and its receptors have long been of interest to scientists 
involved in pharmaceutical research since dysfunction of the glutamatergic signalling pathway has 
been associated with the pathophysiology of several psychiatric and neurological disorders. The 
research on AMPAR positive allosteric modulators offers opportunities to modulate fast excitatory 
synaptic transmission and identify new potential therapeutic agents for a range of neurodiseases. The 
field of AMPAR modulators continues to be a dynamic area of drug discovery with a pronounced 
diversification of the chemotypes explored in recent years. This article reviews literature published in 
this area in the last 6 years, focusing on the new core templates, some derived from high-throughput 
screens, with an emphasis on structure-activity relationships, drug metabolism and pharmacokinetics 
proper-ties, and pharmacological profiles of these series. 
 
GLUTAMATE AND ITS IMPLICATION IN NEURO-PSYCHIATRIC AND NEUROLOGICAL DISORDERS  
In the mammalian central nervous system (CNS), the neurotransmitter glutamate, which is released 
from presynaptic terminals, mediates the greater part of excitatory signal-ling through binding to 
glutamatergic receptors widely distributed on neurons and glia [1]. Glutamate acts on two distinct 
classes of receptors: ionotropic (ion channels) and metabotropic (G-protein coupled receptors) [2]. 
There are three types of glutamate ionotropic receptors named according to the chemical entity 
originally discovered to selectively activate each channel: AMPA (α-amino-3-hydroxyl-5-methyl-4-
isoxazolepropionic acid), NMDA (N-methyl-D-aspartate) and kainite [3]. The pathophysiology of 
several psychiatric and neurological disorders has been associated with glutamate neurotransmission 
dysfunction, such as schizophrenia, Alzheimer’s disease, Parkinson’s disease and mood disorders [4-
6]. Consequently modulation of the glutamatergic signalling pathway attracted the interest of the 
pharmaceutical research community since it could potentially lead to the discovery of innovative 
treatments for a range of conditions. However the complex pharmacology of glutamatergic neuro-
transmission and the absence of highly selective chemical tools have restricted major advancement in 
this neurological area for many years. Recent developments in the understanding of this physiological 
pathway [7] and the identification of novel, rationally designed, AMPA receptor modulators with 
targeted pharmacokinetic profiles represent great promise and could lead to new therapies for a 
range of neurological and psychiatric conditions in the near future.  
Hypofunction of fast excitatory synaptic transmission has been linked to cognition deficit, a major 
symptom in Alzheimer’s disease and schizophrenic patients.[4] In the case of schizophrenia, it has 
been proposed that the disease pre-dominantly originates from NMDA receptors’ (NMDARs) 
glutamatergic synaptic underactivity, with non-selective NMDAR antagonists causing schizophrenia-
like symptoms in healthy volunteers [8,9]. In addition, post-mortem analysis of schizophrenic 
hippocampus has revealed a subnormal density of AMPA receptors (AMPARs) and an increased 
concentration of the glutamate receptor antagonist N-acetylaspartyl glutamate, emphasizing the link 
with hypo-glutamatergic neurotransmission [10]. Dynamic regulation of AMPARs in postsynaptic 
membranes and activation of the receptor are intimately associated with synaptic plasticity, a 
mechanism believed to underlie learning and memory [11,12]. Under normal physiological conditions, 
repetitive AMPAR stimulation induces postsynaptic neuronal mem-brane depolarization, provoking 
colocalized NMDARs activation, following release of the Mg2+ block. This enhances NMDAR Ca2+-
gating [13], which concomitantly with AM-PAR-mediated cation influx eventually results in synapses 
strengthening (synaptic plasticity) [12,14]. In turn, the NMDAR-increased synaptic signalling influ-
ences receptor trafficking and additional AMPARs are in-serted into the synapses.[15]  
STRUCTURE AND MODULATION OF AMPA RE-CEPTORS  
AMPARs are tetrameric complexes, organized as dimers of dimers.[16] Four different subunits (GluA1 
to GluA4), composed of about 900 amino acids and sharing 65 to 75% sequence homology, can 
combine to form homo- or heterodimers, which subsequently combine to form a tetramer.[17] 
Distribution of AMPAR subunits in the CNS has been demonstrated to be uneven between the various 
brain regions, with different cellular expression within each region.[18] Over the last decade, single 
electron microscopy and X-ray crystallography have enabled to develop a better understanding of the 
structure and assembly of the AMPAR subunits.[19] Recently, the combined use of X-ray crystal-
lography and cryogenic electron microscopy has enabled to obtain structural information for GluA2-
containing AMPAR heteromers and has revealed new insights into the dynamic arrangement of the 
extracellular region of the receptor.[20] Each subunit is composed of an extracellular domain, a 
transmembrane domain and an intracellular domain.[21] The extracellular domain comprises a large 
N-terminal region with binding sites for regulatory proteins, and a ligand binding domain (LBD) 
consisting of two discontinuous sub-domains, S1 and S2 arranged in a clamshell motif allowing 
glutamate binding. The transmembrane section is composed of three α -helices (TM1, TM3 and TM4) 
and a re-entrant hairpin loop (TM2), which constitutes part of the ion channel pore.[22] The 
intracellular section of each subunit displays the C-terminal domain, which possesses interaction sites 
for a range of accessory proteins, contributing to AMPARs trafficking and regulation of the receptor 
kinetics.[23–26] A diverse range of subunit assembly can lead to functional  
AMPARs. The composition of the channel in vivo is extremely complicated and influences receptor 
kinetics and glutamate binding. An extra layer of structural diversity arises from the presence of sites 
of post-translational modifications and the existence of splice isoforms, known as flip (i) (Ser775; 
UniProt ascension number P42262-2) and flop (o) (Asn775; UniProt ascension number P42262-
1).[27,28] The flip/flop variation, found in the S2 sub-domain of the LBD, controls the kinetics of 
channel closure and desensitization.[29,30] Incorporation of flip or flop isoforms in a tetrameric 
complex is influenced by transmembrane proteins [23].  
In view of the connection of glutamatergic neurotransmission dysfunction with diverse neurological 
and psychiatric disorders, generation of glutamate receptor ligands has been of interest and a range 
of different approaches investigated. In particular, according to the mechanism of synaptic plasticity 
and the causes of cognition deficit in diseases, such as schizophrenia, enhancement of AMPAR-
mediated synaptic transmission has been extensively explored.[31,32] Originally direct or partial 
AMPAR agonists were searched, but it quickly became clear that such compounds were associated 
with high risk of toxicity following over excitation of the receptor signalling.[33,34] This approach 
precluded the precise and refined spatial and temporal control, required for optimal cognitive 
functioning, and was overcome by the discovery of AMPAR positive allosteric modulators (PAMs), 
termed potentiators, which lack intrinsic activity in absence of glutamate. Nonetheless, when AMPARs 
are functionally activated via binding of the endogenous substrate, they enhance the agonistic effect 
by modulating the channel biophysical properties.[35] Potentiators enhance AMPAR response 
through two distinct effects on synaptic currents: inhibiting desensitization and/or slowing 
deactivation.[36] Unlike orthosteric agonists, PAMs maintain the magnitude and/or duration of 
channel opening during synaptic activity. However AMPAR potentiators can still cause excitotoxicity, 
resulting in motor coordination disruption and/or convulsion,[37,38] and therefore carefully 
determining pre-clinical therapeutic indexes of these molecules is critical for onward development. 
The majority of modulators described to date have limited subunit selectivity but excellent selectiv-
ity against the other ionotropic and metabotropic glutamate receptors. It has been hypothesized that 
some AMPAR sub-types might govern the ‘positive’ pharmacology of AMPAR PAMs whereas other 
subtypes might cause the undesired adverse events. Hence selectively targeting the ‘positive’ 
subtypes would prevent side-effects and offer an optimal therapeutic index. Unfortunately it is 
currently impossible to biologically test this assumption.  
After years of intense research, recent studies have established that AMPARs are macromolecular 
complexes with a large molecular diversity.[39] These result from the assembly of the GluA tetramer 
with auxiliary proteins including the transmembrane AMPAR regulatory proteins (TARPs), the 
cornichon homologs (CNIH) and the CKAMP44 protein.[40] Findings into the heteromultimeric nature 
of AMPARs indicate that the receptor functions beyond glutamate binding may be largely influence 
by non-GluA subunit constituents. In particular, members of the TARP family of proteins regulate 
AMPAR trafficking and pharmacology, and also control sensitivity to AMPAR potentiators. [41,42] 
TARPs have different regional expression across the CNS, hence providing the innovative and 
attractive opportunity to modulate AMPARs in specific brain regions to access potentiators with 
potential therapeutic advantage (Fig. 1). This would be achieved by identifying TARP-dependent 
AMPAR PAMs and a similar strategy has recently been successfully implemented by Lilly in their search 
for safer AMPAR antagonists for the treatment of epilepsy.[43] Positive emission tomography studies 
with a range of AMPAR modulators have indicated that different concentrations of potentiators are 
required to selectively activate the CNS regions associated with procognitive and undesired effects, 
suggesting a potential role of localized auxiliary proteins resulting in AMPAR complexes with different 
biophysical properties [44].  
The LBD of the channel has an opened bilobate structure which closes upon binding of glutamate, 
initiating the gating cascade.[45,46] According to X-ray cocrystal structures of positive modulators 
bound to the LBD of AMPAR, all potentiators bind at the S1S2 interface of the LBD, resulting in 
increased stability of the closed glutamate-bound dimer.[47] Several studies have demonstrated that 
the isolated LBD possesses similar pharmacological properties to the native membrane-bound 
AMPAR.[48] This has enabled to significant advance in the understanding of the biophysical and 
structural properties of the channel, allowing structure-based drug design (SBDD) of agonists and 
antagonists, but also the identification of binding sites for PAMs.[49] Irrespective of their mechanistic 
properties and mode of action, AMPAR potentiators have been shown to enhance glutamatergic 
synaptic activity in several in vitro experiments both on recombinant and native tissue 
preparation,[14,50] and improve cognition in preclinical animal models and in small but not all clinical 
trials.[51–55] In addition, AMPAR PAMs have been therapeutically beneficial to treat a range of 
neuropsychiatric and neurological conditions in animal models, such as anxiety, attention-deficit 
hyperactivity disorder (ADHD), Parkinson’s disease and depression.[56–60]  
CLINICAL STUDIES WITH AMPAR POTENTIA-TORS  
Successful medicinal chemistry programmes have delivered a number of clinical candidates that have 
entered clinical development. Encouragingly no major mechanism-related safety issues have been 
reported and some com-pounds have shown promising efficacy in early patient-based studies, 
however no compound has yet demonstrated sufficiently robust efficacy to merit large scale efficacy 
studies. Table 1 summarizes compounds that have entered clinical evaluation but have been 
terminated. 
Cortex pioneered early work in the area and reported positive clinical data on early compounds such 
as CX516, which demonstrated positive effects in studies with healthy volunteers[55] and as an 
adjunct therapy in patients with schizophrenia.[61,62] The early promise with CX516 did not continue 
as the compound failed to demonstrate efficacy in a number of later studies when tested in patients 
with mild cognitive impairment,[63] autism[64] or Alzheimer's Disease.[65] A subsequent compound 
CX717 (structure has not yet been revealed) also showed equivocal efficacy results, failing to 
demonstrate beneficial effects in healthy subjects[66] but demonstrating efficacy in ADHD 
patients.[67] Cortex failed to obtain funding to follow up on the positive results seen in patients with 
ADHD, however they are still developing CX717 for respiratory depression (Table 2). Cortex have also 
taken another compound CX691 into the clinic for psychiatric indications either alone or following 
licensing deals with other companies, but the com-pound failed to demonstrate beneficial effects.[68–
70] Organon, Lilly and GlaxoSmithKline (GSK) have also reported negative data.[63,71–74] 
Understanding the factors which have contributed to the positive results seen with some com-pounds 
and the failures with others has been and will be key in the design of the next generation of AMPA 
modulators.  
A number of AMPAR modulators remain under clinical investigation (Table 2). Cortex is again a leading 
player in the field, and have changed their therapeutic focus from psychiatric indications to respiratory 
conditions and consequently have changed the company name to RespireRx. They are currently 
progressing three compounds for sleep apnoea and drug induced respiratory depression.[75] The only 
company currently known to be active in the psychiatry area is Pfizer with a compound PF-4958242 
11 in Phase I studies. A total of eleven Phase I studies have been con-ducted over an extended period, 
[76] many of these studies focus on pharmacokinetic evaluation of investigation of drug-drug 
interaction potential, and suggest that there are potentially a number of safety concerns with the 
compound. The results of one study with PF-04958242 have been published, where it showed 
beneficial effects in treating age related hearing loss.[77]  
CHEMOTYPES OF AMPAR POSITIVE ALLOSTERIC MODULATORS  
A number of excellent comprehensive reviews, describing the historical chemotypes originally 
explored as selective AMPAR positive modulators, have been published in recent years.[78–80] Briefly, 
three major classes have been explored: the benzamides, the thiadiazines and the phenethyl 
sulfonamides. Chronologically, the benzamide series, derived from the nootropic agent aniracetam 1, 
was first looked into and developed by Cortex into derivatives such as CX516 2, CX691 3 and ORG26576 
4, which were all tested in the clinic. Then the thiadiazine series, originating from the diuretic agent 
cyclothiazide 5, was also extensively investigated, leading to Servier’s clinical candidate S-18986 6. 
Finally, a class of phenethyl sulfonamides, discovered by Lilly, generated significant interest with a 
number of subsequent patent applications from several pharmaceutical companies also covering 
sulfonamide derived structures. This class has yielded candidate compounds including LY451395 7 and 
LY450108 8 from Lilly, GSK729327 9 from GSK and PF-04958242 11 from Pfizer. Over time the 
modulators developed have become increasingly more potent for the AM-PAR, with the original 
benzamides being weaker than the phenethylsulfonamides. [78]   
As highlighted in our 2015 review of the AMPAR patent literature,[81] a number of novel chemotypes 
have recently been discovered, some of which are suggested to have a different mode of action and 
potentially a different clinical profile. This article will concentrate on new developments reported in 
the scientific literature over the last six years and not fully covered by previous reviews. We will mainly 
focus on the new core templates, some derived from high throughput screens (HTS), with an emphasis 
on structure activity relationships (SARs), drug metabolism and pharmacokinetics (DMPK) properties 
and pharmacological profiles of these series. Whilst only GSK and Pfizer have described in detail the 
discovery and profiles of development candidates (9, 10 and 11), [82, 83, 44] other organisations have 
published descriptions of a range of different chemotypes for which no development has been 
reported. It is also interesting to note that many recent scientific articles and patents in this area have 
been published by academic groups with a reduced number coming from industrial laboratories, this 
perhaps has been influenced by the decision of many companies to withdraw from the neuroscience 
area, and also in some cases the move of experts in this area from industry to the academic sector.  
TWO NOVEL TEMPLATES FROM GSK  
Between 2005 and 2010, GSK have filed a large number of patent applications for novel AMPAR 
modulators, indicating a strong interest of the company in this area of neuro-science [84–95]. In the 
period covered by this review, they published three scientific articles, each focusing on a different 
chemotype [82, 83, 96]. 
Table 1. Compounds which entered clinical evaluation but for which progression has been 
terminated 
 
 
 
Table 2. Compounds currently under active clinical investigation 
 
 
Fig. (1). Representative chemotypes of AMPAR positive allosteric modulators. 
In a short communication,[96] they reported the discovery of a series of N-substituted pyrrolidines 
and tetrahydrofurans, related to the phenethyl sulfonamide modulators de-scribed by Lilly. We can 
assume that this exploratory work, based on existing literature, was conducted when the company 
first started to develop an interest in this area and can be considered as GSK’s initial attempt to identify 
AMPAR positive modulators. The original Lilly phenethyl sulfonamide series generally suffered from 
poor physicochemical properties, such as low solubility, high polar surface area and high lipophilicity, 
which might have contributed to the failure of the compounds which progressed to the clinic 
(LY451395 7 and LY450108 8). By introducing heteroatoms on the phenethyl moiety, using 3,4-
disubstituted pyrrolidines (Fig. 2) and 3,4-disubstituted tetrahydrofurans (Fig. 3) link- 
ers, and exploring replacement for the N-phenyl methanesulfonamide motif, the GSK team was 
attempting to modulate these undesired properties. Interestingly the reported pyrrolidine linker 
derivatives have relative trans stereochemistry whereas the tetrahydrofuran (THF) linker derivatives 
have relative cis stereochemistry. This renders direct comparisons between the two sub-series 
challenging and it is assumed that direct matched-pairs have not been prepared, since according to 
the authors these stereochemistry were only selected because of their synthetic tractability. The 
compounds were screened for their ability to potentiate glutamate-induced calcium influx against 
recombinant hGluA2i receptors in a Fluorometric Imaging Plate Reader (FLIPR) based assay, with the 
maximal response of cyclothiazide defined as 100%.  
Rigidification of the linker and introduction of a heteroatom in this part of the template was well 
tolerated since the first derivative prepared 12 (R = Me) induced strong potentiation of the hGluA2i 
recombinant receptor (EC50 = 0.3 µM, Asym Max = 124%). Different substituents on the pyrrolidine 
nitrogen were investigated (12 and 13, R = Me, Et,  
iPr, Ph) and showed that N-methylated pyrrolidines afforded the best activities with bulkier groups 
leading to decreased potentiation. Reduction of the polar surface area was examined by replacing the 
meta methylsulfonamide moiety by a para nitrile in 13 or various meta substituents in 14, such as a 
methylsulfone, an acetamide, a methylketone or a trifluoromethyl group. All of these modifications 
resulted in at least a 10-fold loss in potency. Changing the phenyl ring for a pyridyl 15 (R = R’ = H) or a 
substituted pyridyl 15 (R = H, R’ = F or R = F, R’ = H) produced compounds with higher EC50s than 12 
(R = Me), in the micromolar range (2.5 to 5 µM). Thiophenes were also tried as potential phenyl 
replacement but afforded weaker compounds (16, R = 2-thiophene, EC50 = 20 µM; 16, R = 3-
thiophene, EC50 = 3.2 µM).  
A major downside of the majority of these pyrrolidine-linked isopropylsulfonamides was an undesired 
off-target inhibition of the hERG cardiac channel. Despite a reduction in lipophilicity, these molecules 
contain a basic centre, a common feature in compounds with affinity for hERG, and 
 
Fig. (2). Representative structures of the pyrrolidine-linked isopropylsulfonamide derivatives. 
some derivatives were very potent hERG inhibitors, such as 12 (R = Ph, hERG IC50 = 1.3 µM) or 15 (R 
= F, R’ = H, hERG IC50 = 1.0 µM). An increase in solubility was success-fully achieved, with compound 
12 (R = Me) and 13 (R = Me) achieving levels of > 9 mg/mL and > 2.7 mg/mL, respectively. Intrinsic 
clearance was high in both rat and human liver microsomes (RLM and HLM) for N-methylated 
derivatives, with N-dealkylation being identified as a major route of metabolism. Compounds with 
larger N-substituents generally achieved good microsomal stability but had similar or higher affinity 
for hERG relative to AMPAR. It was hypothesized that substituting the pyrrolidine ring by a THF could 
mitigate the hERG and metabolic liabilities of this series and afford selective compounds with a better 
pharmacokinetic profile. 
 
Fig. (3). Representative structures of the tetrahydrofuran-linked isopropylsulfonamide derivatives. 
All the THF analogues reported (7 in total) showed excellent potentiation of the AMPAR (EC50 < 0.5 
µM; Asym Max > 112%) and were significantly more active than the N-methyl pyrrolidine derivatives. 
This could be explained by the reduced steric bulk of the THF and also possibly by the different relative 
stereochemistry. The calculated lipophilicity and polar surface area of the THF derivatives was lower 
than that of the pyrrolidine analogues. With the exception of 17 (R = CN, R’ = H) and 18 (R = F, R’ = H), 
all the molecules in this subseries had more than 100-fold selectivity for hGluA2i over hERG. 
Unfortunately only a limited set of in vitro DMPK data was reported for these THF modulators and it 
is impossible to know if these molecules successfully achieved the targeted properties discussed 
earlier. Indeed, the intrinsic clearance of only two analogues 18 (R = H, R’ = F) and 19 (Het = 2-(5-F)-
pyridyl) was disclosed and both com-pounds had high turnover in RLM. In addition, no solubility or 
CNS permeability data are given for the THF derivatives.  
The limited success in identifying AMPAR modulators with desirable physicochemical and 
pharmacokinetic proper-ties starting from a literature chemotype probably prompted GSK to identify 
their own chemical hits through screening of in-house compound libraries. Hence in a second 
publication from 2010, scientists at GSK reported the discovery and optimization of indane clinical 
candidate 9. [82] From this publication, it appears that the indane series was the first novel chemical 
core extensively explored by GSK in their search for AMPAR positive modulators. Interestingly in 
addition to a high potency, scientists at GSK were also targeting a specific pharmacokinetic profile, 
which would deliver high unbound compound concentrations. In this respect, the article not only 
presents the SAR around the indane core but also detailed in vitro and in vivo DMPK data, which led 
to the selection of the clinical candidate.  
The exploratory work in this series started with the identification of lead amino indane 20, a rigid 
analogue of the phenethyl series, which comprises the two sulfonamide moieties of Lilly’s clinical 
candidate LY451395 7. Com-pound 20 induced significant potentiation of the AMPAR-mediated 
response against recombinant hGluA2i receptors in a FLIPR-based fluorescent-indicator dye assay 
(pEC50 = 6.1, Asym Max = 123%). Owing to its encouraging calculated physicochemical properties (see 
Table 3), lead 20 was pro-filed in an array of in vitro assays, and found to have accept-able rat protein 
plasma binding (95.9%) and good selectivity for AMPAR over closely related ion channels. Additionally, 
it did not cause CYP450 inhibition at low concentrations but was identified as a moderate P-gp 
substrate with a moderate efflux ratio (ER = 5.8) in the permeability MDCK-MDR1 assay. This was 
assumed to be caused by the high polar sur-face area (PSA) (92 Å²) and resulted in low CNS penetration 
in a rat oral pharmacokinetic study (Table 1, brain:blood ratio = 0.1) despite good systemic exposure. 
Table 3. Physicochemical and DMPK properties of lead compound 20 
 
With the preliminary SAR indicating that modulation of the isopropylsulfonamide moiety was not 
tolerated, attention turned to modification of the phenyl ring. Deletion of the meta substituent and 
introduction of ortho or para groups led to a significant reduction in potency. A broad range of 
alternative meta substituents were investigated but none retained the activity of compound 20, with 
the exception of sulfonamide derivatives (secondary and tertiary), but which also maintained 
undesirable high PSA. In vivo exposure of some of these potent analogues was determined in rat 
pharmacokinetic studies but similarly to 20 all suffered from poor CNS penetration. As a result, a 
number of aromatic rings with significantly lower polar surface area was explored, with the objective 
to reduce affinity for P-gp while maintaining high free drug concentration and good potency. This led 
to the identification of 3-pyridyl and 2-pyridyl indane analogues (21, R = H and 22, R = H). Although, 
unsubstituted 3-pyridyl analogue 21 (R = H) had lower potency in the FLIPR assay (pEC50 = 4.8, Asym 
Max = 101%), inhibited CYP isoform 1A2 (IC50 = 0.6 µM) and was moderately stable in rat microsomes 
(Cli = 2.1 mL/min/g), it possessed significantly improved physicochemical properties, such as lower 
PSA (59 Å²), molecular weight (316 g/mol) and clogP (2.3). These pyridyl derivatives were deemed 
interesting starting points for the identification of compounds with improved CNS penetration and a 
series of close analogues was prepared. To avoid an increase of the polar surface area (PSA < 60 Å²), 
pyridyl substituents were limited to alkyl and halo groups. 
 
Fig. (4). Chemical structure of the racemate pyridyl indane derivatives.  
In the 3-pyridyl indane series 21, introduction of a single substituent at any position of the pyridyl ring 
prevented CYP450 inhibition, but only para-substitution provided stronger potentiators (21, R = 6-F, 
pEC50 = 5.3, Asym Max = 106%; 21, R = 6-Me, pEC50 = 5.5, Asym Max = 107%). Intrinsic clearance 
across this set of substituted 3-pyridyl analogues was variable, all compounds had noticeably higher 
human microsomal turnover than the unsubstituted pyridyl 21 (R = H) and the fluoro analogues were 
generally more stable than the methyl substituted pyridines. The same pattern in terms of potency 
(22, R = 5-F, pEC50 = 5.2, Asym Max = 114%; 22, R = 5-Me, pEC50 = 5.5, Asym Max = 90%), CYP450 
inhibition and microsomal stability was observed in the 2-pyridyl indane series 22. To validate the 
initial hypothesis that a reduction in PSA would increase CNS exposure, a selection of compounds from 
these series (21 and 22) with lower PSA than 20 were assessed in rat in vivo pharmacokinetic studies 
and found to have significantly improved brain to blood ratios (21, R = 2-F, brain:blood ratio = 1.5; 22, 
R = 6-Me, brain:blood ratio = 1.4) (Fig. 4). 
 
Fig. (5). Structure of the three enantiopure indanes extensively profiled.  
The exploratory work described above was conducted using racemic mixtures of indanes, comprising 
R and S enantiomers. Testing of single enantiomers indicated that the S enantiomers were significantly 
more potent, hence further exploration and characterisation then focussed on derivatives with the S 
stereochemistry. Three enantiomerically pure modulators (9, 23 and 24) were profiled in detail. 
Indanes 9, 23 and 24 all produced good potentiation of AMPAR in the FLIPR assay, did not inhibit the 
CYP450 isoforms tested and retained the good microsomal clearance of the racemic mixtures, with 
methyl derivative 23 having higher intrinsic turn over than fluoro derivatives 9 and 24. In a whole-cell 
patch clamp electrophysiology assay, these compounds also showed clear potentiation of AMPAR-
mediated currents over a range of concentrations in HEK293 cells expressing hGluA2i homomeric 
receptors. Furthermore, all three derivatives (9, 23 and 24) had excellent selectivity against a wide 
range of ion channels, enzymes and GPCRs. When tested in two in vivo behavioural cognition models, 
compounds 9 and 24 had a significant effect. Administration of both com-pounds at 0.3 mg/kg (PO) 
improved recognition memory of male rats, in the 24 h delay-induced deficit in a novel object 
recognition (NOR) experiment. [97] In the passive avoidance task assay,[98] modulator 9 attenuated 
the scopolamine-induced amnesic effect when administered at 3 and 10 mg/kg (PO), while compound 
24 was active at 1 and 3 mg/kg (PO). Based on the efficacy and DMPK data, only derivatives 9 and 24 
were progressed to safety and tolerability studies. From these studies (no direct comparison is given), 
9 was selected as the development compound (Fig. 5).  
The binding mode of the indane series was determined from a 1.8 Å resolution crystal structure of the 
functional hGluA2i S1S2 ligand binding domain in complex with modulator 9 (PDB code 2xhd; Fig. 6). 
The compound was found to bind in an analogous manner to the phenethyl sulfonamides described 
by Lilly, with the isopropylsulfonamide moiety pointing into one of the two deep hydrophobic pockets 
present at the dimer interface and the sulfonamide NH making a hydrogen bond with the backbone 
carbonyl of Pro515.  
Clinical candidate 9 had low equilibrium solubility (≤ 0.1 mg/mL) across the range of pH (2 to 10) and 
physiological fluids (water, simulated gastric fluid, and simulated intestinal fluid) tested, but high 
permeability (Papp (+inh) = 688 nm/s; ER = 1.1), which delivered attractive pharmacokinetic profiles. 
Indeed, 9 had good oral bioavailability (51 to 61%) and low blood clearance (3 to 11% liver blood flow) 
in the three preclinical species tested (rat, dog and monkey). In addition to these suitable 
developability properties, compound 9 had excellent solid and solution stability under a range of 
conditions, did not induce time-dependent inhibition of CYP450 and no formation of glutathione 
conjugate was detected, eliminating the potential liability associated with the presence of the α-
fluoropyridine. AMPAR modulator 9 induced weak PXR activation in both rat and human, and as such 
only had a low propensity for drug-drug interactions through induction of CYP3A4. The in vitro plasma 
protein binding of the compound was measured in five species (mouse, rat, dog, monkey and human), 
found to be moderate (from 79.5 to 90.8%) with low interspecies variability, and was fitting with the 
targeted pharmacokinetic profile sought by the GSK group.  
A metabolite identification study was conducted using in vitro rat, dog, monkey and human 
microsomes. Five metabolites were observed at low abundance relative to the parent drug, and all 
metabolites detected in HLM were also present in the other microsomal species. Three metabolites 
resulted from hydroxylation of the aliphatic part of the indane ring and one of these was a major 
metabolite across all species.  
Oxidation of the isopropyl moiety was also detected but rep-resented a minor route. Aryl 
hydroxylation was the final metabolic route identified and was only significant in rat microsomes. 
Furthermore, development compound 9 was not genotoxic in the selected in vitro genetic toxicity 
screens and did not exhibit any cardiovascular risk in an in vitro hERG assay or following single oral 
dosing up to 2.5 mg/kg in cynomolgus monkeys. Finally, clinical candidate 9 had no observed adverse 
effect levels and acceptable safety margins in preclinical safety screening up to 6 weeks. All of these 
results prompted evaluation of 9 in the clinic.  
 
Fig. (6). X-ray crystal structure of clinical candidate 9 in complex with hGluA2i S1S2 LBD (PDB code 
2xhd, 1.8 Å resolution)* 
* All the X- Ray images presented in this review were generated using Maestro, version 10.5, 
Schrödinger, LLC, New York, NY, 2016 
An initial phase I study was conducted in healthy volunteers to explore the safety and tolerability of 
the candidate, as well as its pharmacokinetics in human. Two dosing regimens were investigated: 
single doses (0.25 to 6 mg) and multipledose of 0.1 mg administered daily for 28 days. In both cases, 
indane 9 was rapidly absorbed (Cmax reached between 0.5 and 3 h post-administration) and had a 
very long half-life (107-168 h). This resulted from a very low apparent oral clearance and a large 
apparent volume of distribution, in excess of total body water. This pharmacokinetic profile was not 
predicted from preclinical species and prevented further clinical evaluation of the compound. 
Importantly, both dosing regimens were well tolerated with no safety issues raised or withdrawal 
caused by adverse events (Fig. 8).  
In a third publication from 2011, GSK report the identification of a novel chemical series originating 
from a high-throughput screen and optimized using ligand-bound X-ray crystal structures.[83] The 
optimization work in that series led to the identification of GSK second clinical candidate, compound 
10. The HTS was run using a FLIPR-based fluorescent indicator dye protocol in HEK cells expressing re-
combinant hGluA2i receptors, indicating the ability of the screened molecules to potentiate 
glutamate-induced calcium influx. Despite a moderate AMPAR potentiation (pEC50 = 4.6, Asym Max 
= 94%) in the FLIPR assay relative to other hits, compound 25 was selected as an attractive starting 
point from the screen output because of its superior preliminary developability profile. Indeed, hit 25 
had good physicochemical properties (MWt =  337 g/mol and logD = 3.0) and performed well in a 
battery of in vitro as-says. The molecule had moderate protein binding (plasma and brain), was devoid 
of significant CYP450 inhibitory activity, and had good selectivity against a range of ion channels, 
receptors and enzymes. Low kinetic solubility and high metabolic turnover in microsomes (rat Cli = 
12.7 mL/min/g; human Cli = 3.5 mL/min/g) were identified as the major shortcomings of 25 and 
resulted in low systemic exposure (AUC0-t = 78 ng·h/mL) when the compound was tested in a rat 
pharmacokinetic assay. However in that assay hit 25 had good CNS exposure (brain:blood AUC0-t ratio 
= 1.3), suggesting high permeability. 
In order to rapidly identify a development candidate, the screening cascade used in the optimization 
work not only relied on in vitro functional efficacy screens (FLIPR assay and electrophysiology), but 
also extensively on physicochemical properties calculation. Unusually for a membrane-bound ion 
channel target, X-ray crystallography was also routinely employed enabling SBDD and a focused 
exploration of chemical space to quickly access highly potent modulators and identify a clinical 
candidate. The crystal structure of tetrahydroindazole 25 in complex with the rat GluA2i S1S2 LBD and 
glutamate was determined at 1.55 Å (PDB code 2xx8; Fig. 7), and indicated that the phenyl ring sits at 
the S1-S2 interface on the 2-fold axis, similarly to other AMPAR PAMs. The trifluoromethyl group 
occupies one end of the inverted U shaped binding pocket and has displaced a cluster of four water 
molecules, while the carbonyl of the amide points down into the symmetrical end of the inverted U, 
making a hydrogen bond with one of the four water molecules. The aliphatic part of the 
tetrahydroindazole heterocycle makes contact with solvent, suggesting that modification of this ring 
might not be tolerated. Several serine residues, which can interact with small-molecule modulators 
via hydrogen bonding, are present in the binding pocket but were not exploited by hit 25. The 
dimethylamide group was identified as amenable for modification and as a handle to potentially reach 
Ser750, Ser775 or the water molecules as hydro-gen bonding partners.  
The hit optimization campaign focussed on improvement of potency, solubility and also metabolic 
turnover. The high metabolic clearance of compound 25 was assumed to be caused by the 
dimethylamide moiety and other acyclic am-ides (26, R = CH2CH2Ph or R = Bu) where one of the 
methyl groups was replaced by a larger substituent were prepared. These derivatives retained similar 
potency to 25 but had reduced solubility and similar or higher microsomal instability. 
 
Fig. (7). Chemical structure of hit 25 and its X-Ray crystal structure with the hGLuA2i S1S2 LBD (PDB 
code 2xx8, 1.55 Å resolution). 
 
Fig. (8). Chemical structures of the tetrahydroindazole derivatives investigated during the lead 
optimization program 
Attention then turned to cyclic amides (10 and 27 (X = CH2 or O)), which were predicted to fit optimally 
in the binding pocket according to the crystal structure of 25 (Fig. 7) and were expected to have 
reduced metabolic instability. Inter-estingly in the FLIPR assay pyrrolidine derivative 10 was more 
potent than 25 (pEC50 = 5.0, Asym Max = 123%), while six-membered ring analogues 27 were less 
active (X = CH2, pEC50 < 4, Asym Max = 100%; X = O, pEC50 < 4.7, Asym Max = 81%). Despite its 
moderate po-tency, morpholine derivative 27 (X = O) had an attractive profile since it retained similar 
solubility to 25, did not cause CYP450 inhibition and had significantly improved metabolic stability in 
both RLM and HLM (rat Cli < 0.5 mL/min/g; human Cli = 1.3 mL/min/g). Encouragingly, compound 10 
was also more stable than 25 when tested in microsomes (rat Cli = 2.4 mL/min/g; human Cli < 0.5 
mL/min/g). Derivatives 10 and 27 (X = O) had good physicochemical properties (MWt < 380 g/mol and 
logD < 3.1), high permeability in an artificial membrane permeability assay (10, 415 nm/s; 27 (X = O), 
455 nm/s) and moderate to high rat plasma and brain protein binding. Owing to their favourable in 
vitro pro-file, compound 10 and 27 (X = O) were progressed to a rat in vivo pharmacokinetic study and 
found to have good systemic exposure (10, AUC0-t = 472 ng·h/mL; 27 (X =  O), AUC0-t = 1984 ng·h/mL) 
with reduced blood clearance rela-tive to the HTS hit. Both compounds also retained high CNS 
penetration (brain:blood AUC0-t ratio > 1) comparable to 25. Interestingly a cocrystal structure of 
amide 10 (PDB code 2xx7; Fig. 9) showed a similar binding mode to compound 25, with an unpredicted 
reorientation of the amide carbonyl and differences in the network of water molecules. The carbonyl 
group of 10 is making a hydrogen bond with a water molecule, sitting at the top of the benzene ring, 
and which is itself making a second hydrogen bond with Ser518. In the meantime, the pyrrolidine ring 
has displaced one of the four water molecules found at the end of the inverted U shaped binding 
pocket.  
Replacement of the amide moiety with a sulfonamide, a ketone or a sulfone was also investigated but 
afforded com pounds with lower or at best similar potency to hit 25. Kinetic solubility of these 
derivatives was also significantly low. Owing to the difficulties in balancing high potency and DMPK 
properties, introduction of a linker atom between the phenyl and the amide group was explored and 
this modification was suggested to be tolerated by docking studies. Such molecules were expected to 
have an increased flexibility that would lead to a superior solubility. The homologated analogue of 25, 
compound 28 (R = R’ = Me), induced a substantial increase in calcium influx in the FLIPR assay (pEC50 
= 5.7, Asym Max = 107%) but retained high microsomal turnover. The SAR in this series appeared to 
be quite narrow since a close acyclic homologated amide 28 (R = cPen, R’ = H) had reduced efficacy 
and very high microsomal clearance (rat and human Cli > 45 mL/min/g). The successful improvement 
in metabolic stability with cyclic amides 10 and 27 (X = O), prompted the GSK team to look at similar 
structural transformation in the homologated series (29 and 30). Derivative 29 (R = R’ = H) maintained 
the improved potency of 28 (R = R’ = Me) (pEC50 = 5.5, Asym Max = 82%) but also the undesired high 
microsomal instability (rat Cli = 14.6 mL/min/g; human Cli = 24.9 mL/ min/g). When both compounds 
were tested in a rat in vivo pharmacokinetic experiment, moderate systemic exposure and high blood 
clearance were observed, emphasizing the need to identify compounds with much improved 
metabolic stability. The initial attempt to enhance metabolic stability focussed on blocking the 
benzylic position of 29 (R = R’ = H), a likely site of metabolism, by introduction of small alkyl and 
fluorine groups. Monomethyl, cyclopropyl, mono and bisfluorinated analogues 29 were prepared, but 
all gave reduced potency relative to methylene benzylic modulator 29 (R = R’ = H) and retained high 
metabolic turnover. The methylene spacer not only created a potential site of metabolism but also 
increased the electron density of the phenyl ring, making it more prone to oxidation. Lowering the 
aromatic electron density by introduction of substituents was considered but had to be limited to 
fluorine atoms since the crystal structure of 29 (R = R’ = H) (PDB code 2xxh; Fig. 10) indicated that the 
benzene ring was in a narrow channel and that large substituents would not be tolerated. 
Fluorophenyl analogue 30 was synthesized and had superior potency to 29 (R = R’ = H) (pEC50 = 5.9, 
Asym Max = 79%), slightly better human microsomal stability but significantly reduced solubility 
(Fig.8). 
The lack of success in identifying homologated amides with a favourable in vitro DMPK profile 
prompted scientists at GSK to consider reversed amides with an embedded benzylamine core motif 
(31 and 32). Tertiary 31 (R = R’ = Me) and secondary 32 (R = H, R’ = Et and R = H, R’ = Me) acyclic amides 
were prepared and found to be highly potent (pEC50 > 5.6), but retained high to moderate intrinsic 
clearance in both RLM and HLM (3.3 < Cli < 22.4 mL/min/g). With the previous success of cyclic amides 
10 and 27 (X = O) to yield compounds with reduced turnover, pyrrolidinone 32 (R = H) was synthesised 
and induced excellent potentiation of the AMPA ion channel (pEC50 = 6.0, Asym Max = 132%). Despite 
a similar moderate rat microsomal clearance to 10 (Cli = 2.4 mL/min/g), modulator 32 (R = H) had 
lower systemic exposure (AUC0-t = 231 ng·h/mL) and notably larger estimated blood clearance when 
tested in rats in vivo. Blocking a potential site of metabolism by introduction of a fluorine on the phenyl 
ring in 32 (R = F) success-fully afforded a potent compound (pEC50 = 6.0, Asym Max = 112%) with 
slightly higher intrinsic stability in microsomes (rat Cli = 2.0 mL/min/g; human Cli = 2.9 mL/min/g). 
However this did not translate to a remarkably superior in vivo pharmacokinetic profile and compound 
32 (R = F) did not achieve the blood and brain levels observed with 10. The majority of the reversed 
amides retained some undesired CYP450 inhibition and solubility in this series was variable with the 
cyclic derivatives being the most soluble. Replacement of the amide moiety by sulfonamides, such as 
in 33 (R = H or Me, R’ = Me or cPr or iPr) or in 34, produced active compounds, although moderately 
less potent than the amide analogues, but lacking any CYP450 inhibitory activity. These compounds 
also successfully achieved moderate to high microsomal stability in both rat and human (Cli < 2.5 
mL/min/g) but were unfortunately for the vast majority too poorly soluble to be tested in vivo. 
 
Fig. (9). X-Ray crystal structure of pyrrolidine amide 10 in complex with the hGLuA2i S1S2 LBD (PDB 
code 2xx7, 2.2 Å resolution). 
 Fig. (10). X-Ray crystal structure of homologated amide 29 with the hGLuA2i S1S2 LBD (PDB code 2xxh, 
1.5 Å resolution). 
 
Fig. (11). Indazole derivatives containing a heteroatom in the saturated ring.  
Having failed to identify compounds with low in vitro and in vivo turnover using a range of strategies, 
a selection of compounds was progressed to an in vitro metabolite identification study to develop a 
better understanding of the metabolic liabilities of the series. Interestingly the saturated part of the 
tetrahydroindazole was detected as a major site of metabolism and stabilization of this heterocycle 
was subsequently investigated. Introduction of heteroatoms (oxygen or nitrogen) in the aliphatic part 
of the tetrahydroindazole moiety was explored (Fig. 11) and successfully delivered active compounds 
with much improved in vitro properties. Overall, modulators 35 to 39 had lower intrinsic clearance in 
rat and human microsomes, higher solubility, lower logD, higher free fraction in both plasma and 
brain, and did not inhibit CYP450 enzymes. This resulted in high oral exposure, with low blood 
clearance and good CNS penetration, when the compounds were tested in rat pharmacokinetic 
experiments. These molecules alongside the ones which previously gave the best exposures when 
profiled in vivo (AUC0-t > 400 ng·h/mL) were tested in electrophysiology, selectivity, developability 
and early toxicology screens. From the results of these assays (data not disclosed), a set of five 
molecules (10, 27 (X = O), 33 (R = H, R’ = Me), 35 and 37), with excellent wider selectivity and clear 
potentiation of AMPAR-mediated currents in patch clamp assays, were identified as potential 
development candidates.  
As mentioned earlier, AMPAR positive modulators have a tendency to induce convulsion, a recognized 
sideeffect of this class of drugs.[37] The maximum electroshock seizure threshold (MEST) assay 
enables to identify compounds which reduce seizure threshold and possess an undesirable 
proconvulsant activity.[99] The five selected compounds were profiled in MEST experiments and 
found to be devoid of any proconvulsant adverse effect. With the exception of compound 33 (R = H, 
R’ = Me), all the modulators were clean in preliminary genotoxic screens and were subsequently tested 
in in vivo cognition models. In the passive avoidance task model,[98] only modulators 10, 35 and 37 
attenuated the scopolamine induced amnesic deficit while modulator 27 (X = O) showed no effect. 
The three active molecules were then assessed in the NOR experiment,[97] a second in vivo 
behavioural model to evaluate cognition. In this model, only compound 10 showed a significant pro-
cognitive effect when administered at doses ranging from 0.1 to 1 mg/kg (PO). Hence 
tetrahydroindazole derivative 10, which was identified early in the program, was selected as the 
preclinical candidate and evaluated further in a battery of in vitro and in vivo assays. 
Similarly to hit 25, development candidate 10 exhibited low solubility in water, simulated gastric fluid 
and fasted simulated intestinal fluid. Nonetheless the compound had excellent solution stability in all 
media tested and also high solid stability over time. In addition, compound 10 did not induce time-
dependent inhibition of CYP450 isoforms 2D6 and 3A4, and did not inhibit hERG currents at 10 µM. 
Intrinsic turnover of the molecule was studied in both microsomes and hepatocytes across five 
different species: rat, dog, minipig, monkey and human. Microsomal and hepatocyte clearances were 
correlating well and highlighted interspecies differences, with low to moderate instability in rat, dog 
and human, and high turnover in minipig and monkey. In vivo pharmacokinetic profiling of modulator 
10 in four species (rat, dog minipig and monkey) indicated a good tissue distribution, with a volume 
of distribution at steady state in excess of total body water, a rapid oral absorption (0.5 h to 1 h) and 
variable blood clearance across species (moderate in rat and high in the others). This resulted in short 
half-lives (0.5 to 1.6 h) and moderate to low oral bioavailability (2 to 54%). The general good 
agreement between in vitro and in vivo clearances suggested a likely high systemic exposure in 
humans. In single and repeat dose oral toxicity studies of up to four weeks in rats and dogs, the clinical 
candidate exhibited a safe profile, giving a large therapeutic window. Surprisingly, AMPAR PAM 10 
never entered clinical evaluation and GSK did not report or patent further exploratory work in the 
trifluoromethylpyrazole series. 
HTS AND HYBRIDIZATION STRATEGIES BY PFIZER  
Pfizer is another pharmaceutical group which has ex-pressed a strong interest in AMPAR modulation 
and has filed 4 patent applications between 2008 and 2010.[100–103] The company has published the 
most recent scientific literature in the area, with three journal articles since 2013,[44,104,105] and is 
probably the last pharmaceutical group to have joined the race to discover and commercialize an 
AMPAR PAM. In these recent publications, Pfizer describes the discovery and optimization of two 
chemical series, one of which has led to the discovery of clinical candidate PF-04958242,[44] believed 
to be the only AMPAR potentiator still actively evaluated in clinical trials for neuro-logical disorders. 
The majority of AMPAR modulators described in the literature were identified and characterized in 
vitro using recombinant systems, which do not reproduce the structural complexity of AMPARs found 
in vivo (see introduction) and possess a risk that data generated using homotetrameric receptors will 
not translate reliably in native tissues. To mitigate this risk early in projects, Pfizer developed an assay 
employing mouse embryonic stem (mES) cell-derived neurons, which are expected to represent more 
accurately the considerable heterogeneity of composition of AMPARs found in biological organisms 
and afford composite pharmacological values.[106] This assay, which was optimized for a HTS 
campaign and ran on a FLIPR platform, provided two quantifiable parameters: an EC50 obtained from 
a 9-point concentration-response curve and a maximal efficacy percentage (Emax), normalized to the 
average response to 100 µM of AMPA in the presence of 32 µM of cyclothiazide, which was defined 
as 100%. Screening of a Pfizer com-pound library using this newly developed assay led to the 
identification of dihydroisoxazole (DHI) hit 40.[104] Despite a moderate potency in the FLIPR mES 
assay (EC50 = 4.4 µM), modulator 40 had favourable calculated physicochemical properties and was 
as a result profiled in an array of in vitro DMPK assays (see Table 4). Interestingly compound 40 had 
good permeability with no P-gp liability and moderate clearance in HLM, confirming that it was an 
attractive starting point for an optimization program that would primarily focus on improving the 
potency while maintaining optimal CNS physicochemical and ADME (absorption, distribution, 
metabolism and excretion) properties.  
A co-crystal structure of DHI 40 with the LBD of hGluA2o was determined (PDB code 4lz7; Fig. 12) and 
revealed that the phenyl ring sits on the 2-fold axis and that the acetamide projects into one of the 
deep hydrophobic pocket, similarly to the sulfonamide group in LY451395 7. The pyrrolidine ring 
approaches Asn775 but does not participate in any distinct interaction. Intriguingly, unlike GSK 
researchers, scientists at Pfizer did not comment on the network of water molecules present at the 
dimer interface of the two LBD subunits and their potential displacement or interaction with 
modulator 40. 
Table 4. Physicochemical and DMPK properties of DHI 40 
 
 
 Fig. (12). X-Ray crystal structure of DHI hit 40 with the hGLuA2o S1S2 LBD (PDB code 4lz7, 2.1 Å 
resolution). 
 
Fig. (13). Representative structures of DHI derivatives prepared during the lead optimization 
campaign. 
 Fig. (14). X-Ray crystal structure of compound 42 with the hGLuA2o S1S2 LBD (PDB code 4lz8, 1.85 
Å resolution). 
From this crystal structure, it was initially suggested that replacement of the acetamide by a 
sulfonamide could afford molecules with superior binding affinity since docking of a sulfonamide 
group was providing a better fit for the hydro-phobic pocket. The isopropylsulfonamide of the 
phenethyl series was introduced on the dihydroisoxazole core, giving 41, which was 35-fold more 
active than 40 (EC50 = 123 nM, Emax = 147%), confirming the design hypothesis. Compound 41 
retained desirable CNS drug-like properties (MWt = 369 g/mol, clogP = 3.0, TPSA = 79 Å2), had 
moderate predicted human blood clearance (Cl = 13.5 mL/min/kg), and was permeable with no P-gp 
efflux in the MDR1-MDCK in vitro permeability assay (Papp = 18.6 × 10- cm/s, ER = 1.45). The 
enantiomeric pair of 41 was significantly less active, confirming that molecules with the S 
stereochemistry provided the best fit in the binding pocket. A variety of small amides and 
sulfonamides were prepared to probe the SAR of this part of the scaffold, but all induced a loss of 
potency. Replacing the amide with carbamates or ureas was also unsuccessfully investigated. Removal 
of the pyrrolidine produced an inactive compound (43 (R = H, R’ = F), EC50 > 32 µM), while desfluoro 
racemate 43 (R = pyrrolidine, R’ = H) was only slightly less active (EC50 = 253 nM, Emax = 169%) but 
was attractively slightly less lipophilic (clogP = 2.75).  
Docking of 41 in the crystal structure of 40 was per-formed to identify additional means to increase 
the functional potency of this series, and indicated that the second symmetrical hydrophobic pocket 
could be accessed through substitution of the pyrrolidine. Hence an acetamide was introduced at the 
3-position of the pyrrolidine affording 42, an exceptionally active potentiator (EC50 < 10 nM, Emax = 
143%), whose postulated binding interactions were confirmed by X-ray cocrystal structure (Fig. 14, 
PDB code 4lz8). A tritiated form of this potent modulator was prepared to develop an in-house AMPAR 
competition binding assay. 
The development of a low nanomolar potentiator which occupies both hydrophobic pockets of the 
LBD was done at the expense of the physicochemical properties of 42 (MWt = 427 g/mol, TPSA = 109 
Å2) and resulted in poor permeability and affinity for the P-gp transporter protein (Papp = 3.9 × 10-6 
cm/s, ER = 12.1). Consequently, compound 42 had low CNS exposure in a mice pharmacokinetic study, 
precluding its use in vivo. Therefore the SAR around the pyrrolidine ring was revisited with the 
objective to obtain compounds with lower TPSA and also to remove the aniline moiety which 
represented well-documented concerns.[107,108] From the crystal structure of 40 and 42, it appeared 
that replacing the pyrrolidine with a second aromatic ring would be tolerated, and a series of biaryl 
derivatives was prepared. While phenyl analogue 44 (R = H) had low affinity for AMPARs (EC50 = 3.2 
µM, Emax = 138%), pyridyl derivative 45 retained acceptable potency (EC50 = 294 nM, Emax = 157%). 
Molecular modelling of the biaryl template suggested that a nitrile group at the ortho position of the 
distal aromatic could access the hydrophobic pocket, providing superior binding affinity. This design 
hypothesis was confirmed since racemate 44 (R = 2-CN) had similar potency to 41 (EC50 = 87 nM, 
Emax = 152%) and the S-enantiomer 46 was again the most potent (EC50 < 10 nM). Modulator 46 
retained good calculated physicochemical properties (MWt = 401 g/mol, clogP = 3.8, TPSA = 100 Å2), 
had moderate predicted human hepatic clearance (Cl = 9.67 mL/min/kg) and was highly permeable 
(Papp = 29.1 × 10- cm/s; ER = 1.18). Disappointingly, no additional ADME, s electivity or in vivo 
pharmacokinetic data were given for this very promising compound (Fig. 13). In addition, it should be 
noted that no solubility or CYP450 inhibitory data are communicated on any of the compounds 
described above. [104]  
In this publication, detailed pharmacokinetics and pharmacodynamics were only reported for 
compound 41, despite modulator 46 being in appearance the most attractive compound. In their in 
vivo assessment, the Pfizer group demonstrated a marked interest to the unbound brain compound 
concentration (Cb,u), which determines AMPAR LBD inter-actions, and developed a Cb,u-normalized 
AMPAR-mediated exposure-response continuum to define an acute dose rodent-based therapeutic 
index (TI). Such studies were carried out since AMPAR overstimulation has been associated with ex-
citotoxicity [33, 37, 109] and for this reason defining the toxicity threshold in rodents was viewed as 
crucial by Pfizer scientists before advancing any drug of this pharmacological class to large animal 
safety and efficacy models.  
Potentiator 41 had high rat protein plasma binding (97.3%) and rat brain tissue binding in brain 
homogenates (98.6%). In a rat pharmacokinetic study, following single subcutaneous (SC) dosing (0.2 
mg/kg), compound 41 had a short terminal half-life (t1/2 = 0.4 h), a total brain to total plasma 
concentration ratio of 1.04 and an unbound brain to unbound plasma concentration ratio of 0.54, 
confirming that DHI 41 was CNS-penetrant. The convulsion liability, a recognized side-effect of AMPAR 
PAMs,[109] was first studied in CD-1 mice and detected 5 to 11 min post-dose in one third of the 
animals following SC administration of 0.32 mg/kg of 41 and in all animals at a higher dose (0.56 mg/kg, 
SC). Bioanalysis of brain samples from these mice indicated that a 2.1 nM mean Cb,u of potentiator 
induced convulsion. The same study was repeated in Sprague-Dawley rats where the exposure 
convulsion threshold was similar with a toxic Cb,u of 2.3 nM.  
The efficacy of potentiator 41 was first assessed in a modified version of the cerebellum cyclic 
guanosine monophosphate (cGMP) assay, published by Lilly[110] to evaluate the effect of their 
AMPAR modulators on the accumulation of cGMP, a downstream messenger involved in a signal-ling 
cascade regulating excitatory neurotransmission and neuroplasticity. It was determined that cGMP 
levels in-creased with statistical significance in CD-1 mouse cerebellum 30 min after SC dosing of 0.32 
mg/kg of 41, corresponding to a mean Cb,u of 0.4 nM. Surprisingly, it is not mentioned if the effect of 
41 on cGMP elevation occurred in a dose-dependent manner and as mentioned earlier, this same 
dosing regimen (0.32 mg/kg, SC) also induced convulsion in one third of the mice, supporting the idea 
that lower doses must have been investigated but for which no result is re-ported. Urethane-
anesthetized rats, treated with the NMDAR antagonist MK-801 which induces a schizophrenic state, 
were used as an in vivo model to measure the nootropic electrophysiological effects of 41 
administered intravenously. A minimal effective dose of 0.003 mg/kg (IV) of 41 was required to 
significantly reverse the MK-801-induced schizophrenic effect. From a pilot rat IV pharmacokinetic 
study (0.01 mg/kg), it was extrapolated that the reversal effect which occurred after 5 min 
corresponded to a Cb,u of 0.004 nM, giving a 500-fold TI for convulsion relative to procognitive 
electrophysiological enhancement in rats. In the majority of the pharmacokinetic and 
pharmacodynamic experiments described above, DHI 41 was administered subcutaneously and no 
justification was given in this first publication for choosing this preferred mode of administration, 
which is not desired for clinical evaluation. However in a subsequent article, [105] it was mentioned 
that subcutaneous administration was predominantly used to control the variability in (and rise to) 
Cmax and prevent the generation of any potential first-pass active metabolites. Pfizer did not mention 
if further biological studies were being undertaken with this compound, such as in vivo cognition 
behavioural experiments, or assessment of memory related effects in non-rodent species or if focus 
had shifted to potentiator 46. No additional data has been reported on either compound since 2013. 
From this study, it should be noted that the use of SBDD positively informed GluA2-based SAR and 
allowed to quickly prepare potent modulators.  
In a second publication from 2013,[105] Pfizer presented extensive efficacy and safety profiling on a 
single compound, PF-04778574 47, which was originally disclosed in a patent[100] and for whom no 
medicinal chemistry rational design has yet been revealed. As previously mentioned, AMPAR 
overstimulation can be excitotoxic and AMPAR potentiators have been associated with marked 
adverse events in preclinical studies.[37] Conscious of this risk, Pfizer designed a sequence of in vitro 
and in vivo assays in a selection of preclinical species to assist in the identification of safe compounds 
early in lead optimization campaigns and understand potentiator exposures causing desired versus 
harmful effects. In this paper, the Pfizer scientists reported how they applied their safety and efficacy 
assessment cascade to carefully define a PF-04778574 mechanism-based therapeutic index in mice 
and study its translatability from rodents to higher order species, by developing an interspecies 
exposure response model. 
 
PF-04778574, 47 
Fig. (15). Chemical structure of PF-04778574.  
In the in vitro mES FLIPR assay, which was used for the screening campaign in the work described 
above, PF0477-8574 concentration-dependently enhanced S-AMPA calcium influx through the 
heterogeneous mixture of AMPARs ex-pressed (pEC50 = 6.05 ± 0.19 and Emax = 162 ± 24%). In the in-
house competitive binding assay, modulator PF-04778574 had a Ki of 85 nM and was also found to be 
devoid of any agonistic effect in three different assays, corroborating the assumed mode of action. 
Results from these two experiments confirmed that PF-04778574 was a subtype-independent AMPAR 
PAM. As expected, the compound also potentiated  
the effect of S-AMPA on HEK293 cells expressing either recombinant hGluA2i or hGluA2o in a FLIPR 
assay, with similar efficacy on both isoforms (flip: pEC50 = 7.35 ± 0.11 and Emax = 111 ± 6%; flop: 
pEC50 = 7.05 ± 0.07 and Emax = 112 ± 5%), demonstrating an absence of selectivity between these 
two receptor subtypes. Whole-cell patch clamp electrophysiology on primary cultures of rat cortical 
neurons, expressing native populations of AMPARs, was used to study the functional potency of PF-
04778574 on S-AMPA-evoked currents. In that assay, PF-04778574 clearly increased the electric 
current induced by 30 μM of S-AMPA from a concentration of 30 nM and had an EC50 of 282 nM.  
The protein plasma binding of PF-04778574was measured across a range of species (CD-1 mice, 
Sprague-Dawley rats, beagle dogs, cynomolgus monkeys) and found to be moderate (91.2% to 95.2%). 
Interestingly the brain tissue binding was markedly higher (98.0%) and considered species 
independent.[111] These two parameters were used to calculate the unbound drug concentration in 
the plasma (Cp,u) and the brain (Cb,u) from measured total plasma and total brain concentrations. To 
reduce the number of animals sacrificed in the efficacy and safety pharmacodynamic studies, 
Cb,u:Cp,u ratios in four animal models (mouse, rat, dog and Cb,u:Cp,u ratios in four animal models 
(mouse, rat, dog and monkey) were experimentally determined to subsequently allow calculation of 
a Cb,u from a measured Cp,u, when brain tissues were not collected. This conversion of a Cp,u into a 
Cb,u relies on the assumption that Cb,u:Cp,u ratios are constant over time, which is not always the 
case. The free drug ratios determined in neuropharmacokinetic experiments ranged from 0.42 
(mouse) to 0.73 (monkey), indicating good CNS permeability and low interspecies variability from 
rodents to large animals (< 1.7 fold differences). A number of acute pharmacokinetic experiments in 
different animal models, using alternative mode of administration and various dose of PF-04778574 
were then conducted to obtain a selection of dose-Cb, u-time relationships. 
From these experiments, it should be noted that following intravenous administration of PF-04778574 
(0.2 mg/kg) in rat, the blood clearance was more than twice in excess of total liver blood flow (Cl = 
250 mL/min/kg), the volume of distribution was high (Vd = 4.59 L/kg) and the half-life very short (t1/2 
= 0.24 h), indicating poor systemic stability of PF-04778574 in rats. The compound was noticeably 
more stable in dogs following oral dosage (0.1 mg/kg) with a moderate blood clearance (Cl = 8.01 
mL/min/kg), a high volume of distribution (Vd = 2.1 L/kg) and a moderate half-life (t1/2 = 3.1 h). PF-
04778574 was rapidly absorbed in dogs (Tmax = 0.75 h) and had acceptable systemic exposure (Cmax 
= 56.0 ng/mL and AUC0-∞ = 210 ng·h/mL). In mon-keys, PF-04778574 was administered 
subcutaneously at two doses (0.1 and 0.32 mg/kg) affording a moderate mean half-life (t1/2 = 3.4 h) 
and a Tmax around 2 h. Positively, maximal plasma drug concentration (Cmax) and AUC0-∞ values 
suggested linear pharmacokinetics across this dosing range. Un-fortunately no in vitro clearance 
assessments in microsomes or hepatocytes were given and it is impossible to say if the overall high in 
vivo metabolic turnover of PF-04778574 could have been predicted from the in vitro data. 
Once all the pharmacokinetic studies had been carried out, modulator PF-04778574 was characterized 
in a selection of in vivo pharmacodynamic models to correlate the unbound brain drug concentration 
(Cb,u) with the observed pharmacological effects. To rule out any non-AMPAR-mediated in vivo 
pharmacological effect, PF-04778574 was screened at 10 μM against a panel of 118 enzymes and 
receptors, and found to express a high degree of selectivity for the AMPAR with only minimal 
inhibitory activity on the dopamine trans-porter (IC50 = 0.95 μM).   
The in vivo efficacy of PF-04778574 was first assessed in the cGMP assay similarly to compound 41. 
cGMP elevation in the cerebellum of CD-1 mice occurred dose-dependently and was statistically 
significant from a SC dose of 0.32 mg/kg of drug, the other doses evaluated being 0.1 and 1 mg/kg SC. 
Using the pharmacokinetic models developed in CD-1 mice and assuming linear pharmacokinetics 
across the doses tested, it was determined that Cb,u superior to 1.7 nM would induce significant 
increase in cerebellar cGMP levels. In this paper, Pfizer also suggested that changes in cerebellar cGMP 
levels correlate with the potential of compounds to display adverse events. However it should be 
noted that this assay was originally developed to study the efficacy of the AMPAR modulators but not 
their safety.[110] In urethane-anesthetized rats, a dose of 0.1 mg/kg (IV) of PF-04778574 significantly 
overcame the electrophysiological hypoglutamatergic conditions induced by the NMDAR antagonist 
MK-801. The restorative effect occurred between 5 and 25 minutes post-dose and was projected to 
correspond to Cb,u ranging between 0.98 and 0.35 nM, respectively. Additionally, a 0.03 mg/kg dose 
(IV) of compound, translating to a maximal projected Cb,u of 0.30 nM, was ineffective in this assay, 
indicative of a minimal effective Cb,u close to 0.30 nM. Since modulator 47 improved impaired 
synaptic transmission over a large concentration range, it was then tested in a behavioural cognition 
model, the monkey ketamine-disrupted spatial delayed response (SDR) task.[53] In this behavioural 
model, PF-04778574 was tested over a 100-fold dose range (0.001, 0.01 and 0.1 mg/kg, SC), but only 
significantly reversed the ketamine-induced impaired performance at 0.01 mg/kg (SC), suggesting that 
the compound had a hormetic exposure-response,[112] typical of nootropic drugs. From the 
pharmacokinetic model experiments in primate, this dose projected to a mean Cb,u of 0.38 nM. 
Interestingly the readouts of the two in vivo efficacy models were consistent and suggested that 47 
induced procognitive effects from an unbound brain drug concentration of around 0.35 nM (Fig. 15).  
The amplitude of adverse events caused by AMPAR potentiators is generally progressive, first 
manifesting as disruption of motor coordination and ultimately leading to convulsion. The tremorgenic 
potential of AMPAR modulator 47 was evaluated in mice undergoing an accelerating rotarod assay 30 
min post-dose. In that assay, low doses (0.178 and 0.32 mg/kg, SC) were not associated with a 
decrease animal fall latency and only 0.56 mg/kg (SC) of PF-04778574, projecting to a Cb,u of 4.8 nM, 
induced statistically meaningful motor deficits. In addition to the motor coordination disruption 
observed in the rotarod test, a number of tremorgenic events were unexpectedly recorded during the 
initial pharmacokinetic studies. Hence general tremor was observed in dogs at Cb,u ranging from 6.0 
to 15.6 nM and movement-related tremor/ataxia were detected in monkeys at Cb,u ranging from 8.0 
to 24.1 nM. In these two species, the Cb,u inducing tremorgenic side-effects were similar but were 
two to three-times higher than in mice. Convulsion, a more severe side-effect, which has been 
associated with a significant number of AMPAR PAMs, was assessed in dose-response studies across 
three species (mice, rats and dogs) to evaluate a potential interspecies consistency in Cb,u causing 
convulsions. In CD-1 mice, among the three doses tested (1, 1.78 and 3 mg/kg, SC), only the highest 
two induced general convulsions and this extrapolated to a minimal convulsion causing Cb,u of 9.6 
nM. The delay to observe convulsions following dosing was greater for the 1.78 mg/kg (SC) group (23 
minutes) relative to the 3.2 mg/kg (SC) group (7 minutes), which was consistent with the “threshold” 
nature of this adverse event. In rats, the two highest doses evaluated (3.2 and 5.6 mg/kg, SC) induced 
convulsions and the same dose-dependent adverse event delay as in mice was observed. The 
convulsive exposure threshold in this species translated to a projected Cb,u of 10.7 nM. In dogs, 
tremorgenic events were observed at the low doses investigated (0.2 mg/kg and 0.25 mg/kg, PO), but 
generalized convulsions only occurred following a dose of 0.5 mg/kg (PO) of 47, corresponding to a 
Cb,u of 17.4 nM. The PF-04778574 Cb,u causing convulsion was consistent in rodents (9.6 and 10.7 
nM), slightly higher in dogs (17.4 nM) and could be expected to be even higher in primates, since 
tremorgenic events happened at doses of up to 24.1 nM.  
The data generated showed that motor coordination disruption was the dose-capping adverse effect 
and that PF-04778574 showed adequate separation between Cb,u linked to efficacy and harmful 
effects with TI of 7-13, 16-29 and 22-42 in mice, dogs and monkeys, respectively. Overall, the 
exposure-response physiological effects were mainly consistent across species, suggesting a 
translatable relation-ship from rodent to higher-order species. Escalating unbound brain 
concentrations progressively led from efficacy to cerebellar cGMP elevation to motor coordination 
disruptions to convulsion. From these studies and a number of subsequent assumptions, the scientists 
at Pfizer concluded that PF-04778574, with a projected 8 to 16-fold TI in humans for self-limiting 
tremor, might be safely evaluated clinically as a nootropic drug in schizophrenic patients. Despite this 
conclusion, the compound never entered clinical evaluation and no further results with this AMPAR 
potentiator have been reported since 2013.  
In a final publication from 2015, scientists at Pfizer re-ported the discovery, SAR and optimization of 
clinical candidate PF-04958242 11.[44] In addition to the identification of new templates from HTS 
such as the DHI series described previously, Pfizer also explored modification of Lilly’s biaryl 
isopropylsulfonamide LY451646 48, with the objective to discover a series with improved efficacy, 
selectivity and metabolic stability relative to 48. Synthetic tractability strongly influenced chemistry 
route design to enable library synthesis and quick expansion of the SAR around the biaryl scaffold. 
From their initial studies with AMPAR modulators, the scientists at Pfizer understood the importance 
of identifying compounds with low human pharmacokinetic variability to accurately predict the Cmax 
and prevent occurrence of threshold-mediated adverse events.[113] With this in mind, 
physicochemical properties of virtual targets imparting ADME properties were carefully examined to 
only prepare compounds likely to develop into good oral CNS drugs with the targeted pharmacokinetic 
profile.  
LY451646 48 was tested in the FLIPR mES assay devel-ped by Pfizer to set a benchmark and only 
produced moderate activity (EC50 = 3.4 µM, Emax = 132%). A number of initial design hypotheses, 
including investigation of different vectors around the central aryl ring, replacement of the middle 
benzene with an heteroaliphatic ring and sulfonamide variation/replacement were unsuccessfully 
explored and afforded inactive compounds. Modulation of the linker was more successful, in 
particular introduction of an oxygen be-tween the phenyl and the two-carbon linker resulted in active 
modulators, such as 49. In this ether subset, para-substitution was preferred, mimicking the SAR of 
the all-carbon linker series. Interestingly while the unsubstituted distal aromatic analogue 49 (R = H) 
had similar potency to 48 but was significantly less efficacious (EC50 = 2.44 µM, Emax = 32%), 
introduction of an orthocyano 49 (R = CN) had an opposite effect, giving a less potent compound with 
greater efficacy (EC50 = 7.35 µM, Emax = 218%), suggesting a potential functionally favourable contact 
of the cyano with the AMPAR LBD interface.  
The X-ray crystal structure of LY451646 48 in complex with the LBD of hGluA2o (PDB code 4lz5) 
indicated that the isopropylsulfonamide NH was forming a hydrogen bond with the carbonyl oxygen 
of Pro515 and was occupying one of the deep lipophilic pockets, similarly to modulators of the 
sulfonamide class. The biaryl core was sitting along the two-fold axis, projecting to the symmetrical 
binding pocket. Docking of 49 (R = CN) into this crystal structure indicated that the orthocyano was 
ideally positioned to access the symmetrical hydrophobic space occupied by the isopropylsulfonamide 
at the other end of the inverted U-shaped binding pocket. This binding model prompted the team at 
Pfizer to conformationally restrict the amido-alkoxyethane linker to preorganize the ligand for binding 
and obtain potentiators with superior pharmacological activity. Hence a number of cis and trans 1,2-
dihalo 5- and 6-membered ring were de-signed and prepared. Examination of the physicochemical 
properties of these molecules and consideration of prior finding from GSK on an almost identical 
series, incited Pfizer to focus on cistetrahydrofuran ether analogues (Fig. 16). 
 Fig. (16). Representative structures of the derivatives investigated during the lead optimization which 
led to the identification of PF-04958242. 
A significant improvement in functional efficacy was observed following introduction of the THF-ether 
linker and chiral separation indicated that the (3S,4S)-isomers were notably more potent than their 
(3R,4R)-counterparts. Despite high functional efficacy (EC50 = 217 nM, Emax = 143%) and good 
permeability with no P-gp efflux in the in vitro MDR1-MDCK assay (Papp = 32.3 × 10-6 cm/s; ER = 1.39), 
com-pound 50 (R1 = H, R2 = H) suffered from undesirable high turnover in HLM (Cli = 158 mL/min/kg). 
To improve the metabolic stability, fluorine atoms were introduced on the distal phenyl, which was a 
likely source of CYP450-mediated hydroxylation, and afforded functionally active compounds with 
improved but still suboptimal human microsomal turnover, such as 50 (R1 = F, R2 = H, EC50 = 14.1 nM, 
Emax = 126%, Cli = 89 mL/min/kg) and 50 (R1 = H, R2 = F, EC50 < 10 nM, Emax = 190%, Cli = 39 
mL/min/kg). Reduction of the phenyl ring lipophilicity by adding polar substituents also successfully 
lowered the clearance but concomitantly induced a reduction of potency (51, EC50 = 1.11 µM, Emax 
= 102%) and negatively impacted properties governing CNS permeability (51, Papp = 17.4 × 10-6 cm/s; 
ER = 7.84). Replacement of the orthocyanophenyl with 
6-membered heteroaromatics in 52 (X = N, Y = C or X = Y = N) and 53 caused a reduction of clogP and 
delivered compounds with low HLM clearance, high permeability, no P-gp liability and acceptable 
functional potency (0.62 < 
EC50 < 1.16 µM, 110 < Emax < 161%). A selection of substituted 5-membered heteroaromatic 
derivatives (11, 54, 55) was also synthesized and afforded compounds with superior functional activity 
compared to the 6-membered heteroaromatics. Of these compounds, potentiator 11 which had good 
activity in the FLIPR mES assay (EC50 = 310 nM, Emax = 110%), low HLM clearance (Cli < 8 mL/min/kg) 
and high predicted CNS exposure from the MDR1-MDCK assay (Papp = 19.3 × 10-6 cm/s; ER = 1.05) 
was selected for further profiling.  
An X-ray cocrystal structure of 11 bound to the LBD interface of hGluA2o (PDB code 4x48, Fig. 17) 
indicated that the isopropylsulfonamide was making similar contacts with the protein as in 48, and 
that the cyano group was in the vicinity of Asn775 possibly impacting on the flip/flop selectivity of 
modulator 11.  
The in vitro potency and efficacy of PF-04958242 11 was assessed in a selection of assays to evaluate 
its species, subunit and splice variant selectivity profile. Although no data is given, the authors 
mentioned that 11 was equipotent in mouse and human ES cell-derived neurons, indicating 
interspecies uniformity. In cells expressing recombinant hGluA2 receptors, compound 11 increased S-
AMPA-mediated Ca2+ influx with some selectivity for the flip (hGluA2i (Ser775), EC50 = 24 nM, Emax 
= 124%) over the flop isoform (hGluA2o (Asn775), EC50 = 880 nM, Emax = 124 %). In a whole-cell patch 
clamp electrophysiology experiment on primary cultures of rat cortical neurons, modulator 11 
significantly enhanced S-AMPA-evoked cur-rent (EC50 = 43 ± 10 nM). To ascertain that the 
pharmacological effects observed when testing PF-04958242 in vivo were solely AMPAR-mediated, 
the selectivity of 11 was determined against a panel of 118 human-based ion channels, receptors and 
enzymes. At the concentration tested (10 µM), compound 11 had good selectivity for AMPAR with 
detectable affinity for only three other receptors and enzymes, the most potent interaction being with 
the serotonin transporter (Ki = 530 nM). The plasma protein binding of 11 was moderate in the three 
species tested (rat: 95.2%; dog: 93.0%; monkey: 89%) while its rat brain protein binding was relatively 
high (98.1%), consistent with the moderate calculated lipophilicity of 11 (clogP = 3.54). Inhibition of 
seven major CYP450 isoforms by modulator 11 was low, with only detectable inhibition of CYP2D6 
(IC50 = 18 µM). Unfortunately only this limited set of in vitro ADME properties was given, and 
important parameters, such as compound solubility, hERG inhibition, CYP induction, reactivity with 
glutathione, or genotoxicity, were not discussed. 
 
Fig. (17). X-ray crystal structure of 11 bound to hGluA2o S1S2 LBD (PDB code 4x48, 1.89 Å resolution). 
A similar approach to the one used to study the effects of PF-04778574 in vivo was employed and Cb,u 
(unbound brain concentrations) were calculated for each animal/dose/time/administration mode to 
establish a Cb,u-normalized AMPAR-mediated exposure response continuum for clinical candidate 11, 
enabling to assess AMPAR-dependent activities related to nootropic effects and safety. Single-dose 
neuropharmacokinetic experiments were con-ducted in CD-1 mice and Sprague-Dawley rats to 
determine Cb,u:Cp,u ratios, treated as constant over time, and subsequently allow calculation of a 
Cb,u from a measured Cp,u at multiple time points. The Cb:Cp and Cb,u:Cp,u ratios experimentally 
measured ranged from 0.59 to 1.5, confirming the good CNS permeability of 11 predicted by the 
MDR1-MDCK assay. The neuropharmacokinetic experiments in rat (1 mg/kg, SC; 0.01 mg/kg, IV) 
indicated that 11 had similar terminal half-life, ranging from 0.53 h to 0.76 h, and Tmax (0.75 h) in 
plasma, cerebrospinal fluid and brain. Following intravenous administration in rat (0.2 mg/kg), PF-
04958242 had very high blood clearance (Cl = 169 mL/min/kg), very short half-life (t1/2 = 0.31 h), high 
volume of distribution (Vd = 3.6 L/kg) and low systemic exposure (AUC0-∞ = 20.1 ng·h/mL), indicating 
poor plasma stability in rats. When administered orally to rats (3 mg/kg), 11 was rapidly absorbed 
(Tmax = 0.25 h), had a longer half-life (t1/2 = 0.84 h) and acceptable systemic exposure (Cmax = 134.0 
ng/mL and AUC0-∞ = 175 ng·h/mL), giving a rat oral bioavailability of 58%. In higher order species, 
the half-life was greater (t1/2 = 6.21 h in dogs (0.1 mg/kg, PO), t1/2 = 12.3 h in monkey (0.032 mg/kg, 
SC)), the Cmax was lower and the systemic exposure consistent (in dogs, Cmax = 23.9 ng/mL and AUC0- 
∞  = 158 ng·h/mL; in monkeys, Cmax = 6.87 ng/mL and AUC0- 
∞  = 149 ng·h/mL). 
Elevation of cerebellar cGMP in CD-1 mice occurred dose-dependently 30 min after administration of 
compound 11 and was statistically significant from a dose of 1 mg/kg (SC). From the 
neuropharmacokinetic models previously established in CD-1 mice following SC dosing of 11, it was 
determined that a projected Cb,u of 6.7 nM induced cGMP elevation in CD-1 mice cerebellum. In 
urethane anesthetized rats, a dose of 0.01 mg/kg (IV) of 11 significantly overcame the 
electrophysiological hypoglutamatergic conditions induced by the NMDAR antagonist MK-801, 
projecting to Cb,u ranging between 0.23 and 0.18 nM. The compound was then tested in a second 
behavioural cognition model, the keta-mine-disrupted spatial working memory in the radial arm maze 
(RAM), in which it attenuated the ketamine-evoked memory loss at doses ranging from 0.0032 to 
0.032 mg/kg (SC), protecting to Cb,u between 0.029 and 0.29 nM according to the subcutaneous rat 
pharmacokinetic study. Higher doses (0.1 and 0.32 mg/kg, SC) were ineffective, indicating a hormetic 
exposure response for this nootropic agent. 
The tremorgenic potential of potentiator 11 was assessed in C57BL/6J mice undergoing an 
accelerating rotarod assay 30 min post-dose. In that test, low doses (0.1 and 0.178 mg/kg) were safe 
and only 0.32 mg/kg (SC) of PF-04958242, projecting to a Cb,u of 10.8 nM, induced statistically 
meaningful motor deficits. The convulsion liability of potentiator 11 was not described, although it can 
be assumed from the previous studies that Cb,u superior to 10.8 nM will be required to cause 
convulsion. From these studies, PF-04958242 had a 37-fold therapeutic index in rodents.  
Intrinsic turnover of 11 was studied in rat and dog hepatocytes (rat Cli ≤ 63.6 mL/min/kg and dog Cli ≤ 
7.4 mL/min/kg) and found to be consistent with the respective in vivo clearance. The good agreement 
between in vitro and in vivo clearances, and the moderate human hepatocyte clearance of the 
molecule (Cli ≤ 7.1 mL/min/kg) suggested a likely moderate to high systemic exposure in humans. 
Metabolite identification studies, indicated that compound 11 underwent similar turnover in dog and 
human systems, with THF hydroxylation and O-dealkylation identified as major route of metabolism. 
Studies using major recombinant human cytochrome P450 isoforms indicated that hepatic turn-over 
via CYP2C19 and CYP3A4 would be the predominant human clearance pathway.  
These positive results prompted Pfizer to evaluate PF-04958242 in 90 day regulatory toxicology 
studies in rats and dogs, in which clinical candidate 11 achieved adequate TIs, suggesting that the 
compound could be safely evaluated in the clinic. Simcyp software was used to project clinical 
pharmacokinetic parameters from experimentally determined preclinical data and predicted an 
efficacious dose of 0.3 mg with a 12 h dosing interval. At the time of publication, AM-PAR potentiator 
11 had been tested in 11 Phase I clinical trials and found to be safe and well tolerated in healthy 
volunteers, in patients with age related sensorineural hearing loss and schizophrenic subjects on 
stable doses of antipsychotics and other psychotropic medications. The authors then claimed that 
further clinical studies would focus on evaluating the nootropic effects of 11 in select neurodisease 
populations.  
EVOLUTION AND OPTIMIZATION OF THE COR-TEX CX614 SERIES  
Cortex has worked in the area of AMPAR positive modulators for many years and have identified many 
compounds which have entered clinical evaluation (Table 1 and 2). The majority of the chemical 
information was until recently contained within patents.[114–118] Only the structures of the early 
development compounds (CX516, CX546, CX614 and CX691, Fig. 18) are in the public domain and little 
information is available regarding SAR and DMPK properties of these compounds. Four recent 
publications describe the discovery of further compounds using CX614 as a starting point.[119–122] 
In the first of the papers,[121] the authors describe how CX614 57 was designed using the knowledge 
of how aniracetam 1 binds to the AMPA protein and applying a conformational restriction strategy to 
stabilise the com pound chemically and enhance activity to achieve micromolar potency. The activity 
of the modulators developed by Cortex was assessed using patch clamp electrophysiology on cultured 
rat embryonic hippocampal neurons. The activities were reported as EC2x, which is the concentration 
of potentiator required to double the current flow through the per-fused neuron.  
Initial investigations focussed on exploration of the importance of the fused dioxane ring, analogues 
demonstrated that the oxygen at position 1 was important for retention of activity; analogues in which 
this oxygen was absent were much less active, with the exception of the compound with a carbonyl 
group at position 1 which retained activity. In c-trast, the oxygen at position 4 was not required for 
activity. Introducing a carbonyl group at position 4, together with a fused pyrrolidine, encouragingly 
produced a more potent derivative (58, EC2x = 0.06 µM) than CX614. The discovery of 58 prompted 
further investigations in this area, initially focussing on simple N-alkyl analogues 59. Results indicated 
that a small alkyl group was optimal for potency, with the methyl analogue being the most potent 
(EC2x = 0.1 µM). Larger groups, which included cycloalkyls and branched alkyls, were generally less 
active, and the unsubstituted analogue (59, R = H, EC2x = 5 µM) had similar potency to CX614. 
Compounds were also tested in a ligand binding assay and a good correlation with the 
electrophysiology as-say was observed. Some of the active compounds in electrophysiology also 
showed weak activity when assayed in a rat hippocampal slice preparation.  
In a second publication,[122] Cortex reported further SAR investigations around the N-substituent. 
Initial studies focused on alkyl chains (59, R = alkyl) bearing substituents. Starting from the N-ethyl 
derivative (59, R = Et) work investigated the effect of introducing functionality on the terminal carbon 
atom. A wide variety of groups were tolerated, producing compounds with similar potency to the N-
ethyl derivative (59, R = Et, EC2x = 0.2 µM). The two modifications which showed marginally increased 
potency were the introduction of chemically reactive groups azide (59, R = N3(CH2)2-, EC2x = 0.08 
µM) and isothiocyanate (59, R = NCS(CH2)2-, EC2x = 0.06 µM). Increasing the chain length by one atom 
and appending a nitrile group gave a butanenitrile derivative (59, R = NC(CH2)3-, EC2x = 0.05 µM). The 
indication from this work is that a wide range of functionality is tolerated at this position.  
Further studies investigated the effect of aromatic groups appended to the alkyl chain (60, R = 
Ar(CH2)n). Activity was shown to be dependent on the chain length in the initial studies (Ar = phenyl) 
with two carbon atoms being optimal (EC2x = 0.25 µM), longer (n = 3) and shorter (n = 1) chains gave 
compounds with activity similar to CX614 (Table 5). Working in the two carbon linker series, the 
introduction of small halogen substituents (fluorine, chlorine) at the 3-position of the phenyl moiety 
gave a 10-fold increase in potency, larger or more polar groups resulted in reduced activity or at best 
retention. Substituents in the 2-or 4-position led to reduced potency. Interestingly the 3,5-
difluorophenyl derivative was highly potent in both the electrophysiology as-say (EC2x = 0.005 µM) 
and binding assay (Ki = 0.3 µM). Following the investigations focussed on phenyl substituents, the final 
area of investigation looked at heterocycles, all linked to the core through a two carbon chain. All 
three isomeric pyridines were equipotent with the corresponding phenyl analogues (Table 5). With a 
few exceptions, the general trend amongst unsubstituted 5-membered heterocycles was an increase 
in potency, typically 10-fold compared to the pyridyl groups. A limited range of substituents are de-
scribed for certain heterocycles, thus it is difficult to draw conclusions regarding the SAR. There is a 
suggestion that in the case of the pyrazoles described, a small lipophilic group, such as chlorine, gave 
a further increase in potency.   
No physicochemical property information or DMPK data was given for this series of compounds in the 
papers describing the SAR. However in a subsequent publication[119] the Cortex group referred to 
phenethyl compound 61, stating that despite its potency in a rat in vitro electrophysiology assay (EC2x 
= 0.011 µM), it is only weakly active when tested in an in vivo electrophysiology experiment, similarly 
to related compounds. High metabolism is suggested to explain the discrepancy between in vitro 
potency and in vivo efficacy. Metabolic route studies in RLM showed the major sites of metabolism to 
be the ethyl chain and the saturated carbon atoms of the oxazinone and pyrrolidine rings. The initial 
strategy adopted to improve the metabolic stability was to substitute the alkyl chain linking the phenyl 
group to tetracyclic core such as in 62 and 63. Substitution adjacent to the phenyl group (62) resulted 
in a large reduction of the in vitro potency in all cases. Substitution of the methylene adjacent to the 
tetracyclic core (63) (X = H, R1 = CO2Me, R2 = H; X = F, R1 = ethynyl, R2 = H) did result in compounds 
with comparable potency to the parent compound (61), but these derivatives failed to demonstrate 
improved metabolic stability. 
 
Fig. (18). Amide based AMPAR modulators describes by Cortex. 
Table 5. Influence of chain length and appended aromatic groups on AMPAR modulation 
 
 The second strategy selected was to investigate replacement of the oxazinone ring with a 
pyrimidinone (64, X = CH) or triazinone ring (64, X = N). This proved successful with both the 
pyrimidinone and triazinone showing similar effects in an in vivo electrophysiology assay at 5 mg/kg 
(IP), when compared to 61 which showed very little response. The SAR of the pyrimidinones and 
triazinones regarding chain substitution mirrored that described for 62 and 63, with small lipophilic 
groups on the carbon atom adjacent to the hetero-cycle producing increased potency but substituents 
adjacent to the phenyl ring not being tolerated. Replacing the pendant fluorophenyl group with a 2-
tetrazolyl group resulted in in-creased potency in the in vivo electrophysiology assay. This was 
particularly evident in the triazinone series and was also reported to correlate with increased 
exposure. Having identified compounds with improved metabolic stability, Cortex focussed on 
removing the chiral centre present in the pyrrolidinooxazinone motif, this was effectively achieved by 
appending a cyclopropyl group to the nitrogen of the oxazi-none. Combining the achiral ring system 
with the modifications, which gave optimal metabolic stability and potency, resulted in 65, which was 
active in a rat native tissue electro-physiology assay (EC2x = 0.46 µM), produced an increase in the 
amplitude of fEPSP in vivo (39% at 5 mg/kg, IP) and induced LTP in the rat (1 mg/kg, IP) (Fig. 19). 
 
 
Fig. (19). CX614 analogues with enhanced potency. 
The main issue with compound 65 was its short plasma half-life (0.27 h) and as a result in a fourth 
publication[120] Cortex described how the pharmacokinetic profile of this series was optimized. In 
addition to the short half-life, it was also suggested that 65 had low brain penetration, although no 
data is given. Initially further investigation of the core ring system was performed and replacement of 
the oxazinone with either pyrimidinone or triazinone was investigated, leading to the identification of 
compound 66, which had an encouraging profile. AMPAR modulator 66 was 100% bioavailable in the 
rat, had good half-life in all species tested (rat: t1/2 = 1.7 h; dog: t1/2 = 3 h; monkey t1/2 = 9.5 h), and 
retained the electrophysiological profile of 65 (EC2x = 0.28 µM; 37% increase in fEPSP amplitude at 5 
mg/kg, IP). All four possible combinations of pyrimidinone and triazinone were prepared with 66 
having the best profile. Extensive SAR investigation was subsequently performed looking at 
modifications of the tetrazole, pendant methyl and cyclopropyl groups. Few modifications gave a 
profile superior to 66 with the exception of replacing the cyclopropyl group by a methyl, which 
resulted in a 2-fold increase in the in vivo electrophysiology effect. Wider SAR investigation showed 
that dimeric tetrazole 67 was more potent than 66 (EC2x = 0.016 µM; 59% increase in fEPSP amplitude 
at 1 mg/kg, IP). No pharmacokinetic data was given on the later compound. Since the publication of 
this series of letters in 2011, Cortex has not reported further progress in the CX614 series or on other 
templates the company has explored (Fig. 20). 
 
Fig. (20). Compounds with improved DMPK profiles. 
OPTIMIZATION OF AN HTS-DERIVED HIT BY OR-GANON USING SBDD  
Organon (now Merck) registered four patent applications between 2008 and 2010,[123–126] and 
relatively soon after published a series of three papers[127–129] which describe the discovery of 
advanced lead compounds and their evolution from a HTS-derived hit, compound 68.  
In the first publication, [129] they describe the profile of 68 and strategies used to improve the in vitro 
developability profile with retention of potency. AMPAR modulator 68 had very encouraging in vitro 
functional potency (pEC50 = 6.7; calcium assay in HEK cells overexpressing hGluA1) for a screening hit 
but was poorly soluble (< 1 mg/L) and highly unstable in both rat and human liver microsomes (Cli > 
270 µL/min/mg). To direct the medicinal chemistry, the group made good use of X-ray structures of 
compounds in complex with the LBD of the hGluA2i subunit. Analysis of the binding mode of 68 (PDB 
code 3O28, Fig. 21) suggested that the key interactions responsible for the activity were hydrophobic 
interactions made by (a) the trifluoromethyl on the tetrahydroindazole and (b) the cyclohexyl ring of 
the tetrahydrobenzothiophene. 
Initial efforts concentrated on opening of the saturated ring of the tetrahydrobenzothiophene and 
preparing dimethyl or methyl and ethyl thiophene analogues (69) or introduction of heteroatoms into 
the saturated ring (70). Truncated analogues all exhibited reduced potency (≈ 30-fold in the best case) 
and a modest increase in kinetic solubility (10 mg/L) for some of them. Introduction of an oxygen atom 
into the saturated ring produced compound 70 which retained potency, but this modification did not 
improve solubility or microsomal stability. Attempts to modify the saturated ring of the 
tetrahydroindazole gave similar results and truncation was generally poorly tolerated. Active 
compounds were obtained when the system was fully aromatised and contained nitrogen atoms into 
the 6-membered ring, but this failed to significantly improve the developability characteristics. 
 
Fig. (21). X-ray structure of hit compound 68 in complex with the S1S2 LBD of hGluA2i (PDB code 3O28, 
2.0 Å resolution). 
Further examination of the structural information revealed a hydrophilic pocket close to the space 
occupied by the primary amide function. A series of analogues were pre-pared in which various 
hydrophilic groups were appended to the amide of 71. One of the early analogues (71, R = NMe2, n = 
2) showed modest potency (pEC50 = 5.2) but was successfully crystallised with the hGluA2 ligand 
binding do-main (PDB code 3O29, Fig. 23). Analysis of the structure revealed a weak interaction with 
an aspartic acid residue (Asp781), which had the potential for further optimization. Interestingly both 
the tetrahydroindazole and tetrahydroben-zothiophene were binding similarly to what was observed 
with hit 68.  
Further modification led to a more potent analogue (71, R = NH2, n = 3; pEC50 = 6.4) and an improved 
developability profile (solubility: 38 mg/L; Cli = 17 µL/min/mg (HLM), Cli = 77 µL/min/mg (RLM)). The 
ADME properties of this compound were still suboptimal since the permeability determined in a Caco-
2 assay was low, but the compound was not a P-gp substrate (A-B = 34 nm/s, B-A = 55 nm/s). 
Unfortunately when 71 (R = NH2, n = 3) was tested in an in vivo rat pharmacokinetic study, the poor 
permeability caused low oral bioavailability (7.7%) and poor CNS penetration (brain to plasma ratio = 
0.05), despite the compound demonstrating moderate blood clearance (21 mL/min/kg). Further 
analysis of X-ray data suggested that conformationally constrained analogues, which might enhance 
permeability, would bind well to the protein. Compound 72 was prepared and showed good potency 
(pEC50 = 6.6), which was slightly superior to the corresponding enantiomer (pEC50 = 5.8). Derivative 
72 possessed promising solubility (20 mg/L) and microsomal stability (Cli = 41 µL/min/mg (HLM), Cli = 
50 µL/min/mg (RLM)). However the Caco-2 permeability was still low resulting again in poor 
bioavailability (3.8%) despite low in vivo clearance (2.3 mL/min/kg, rat). Interestingly the brain to 
plasma ratio increased to 1.03:1.  
Following extensive exploration of the tetrahydroben-zothiophene motif, which failed to deliver 
molecules with the desired in vivo profile, attention focussed on the tetrahy-droindazole group.[128] 
Structural data suggested that introduction of polar groups in this region was possible and could 
potentially interact with two key residues, namely Pro515 and Ser750. Compounds with an opened 
saturated ring and basic functionality appended to the pyrazole ring were modelled as having the 
greatest potential. A series of analogues 73 was prepared; a wide variety of small alkyl groups were 
tolerated and good activity (pEC50 ≥ 6) was observed with both secondary and tertiary amines. Two 
secondary amines were chosen for further study: 73, R1 = Me, R2 = H; pEC50 = 6.5, Cli < 12 µL/min/mg 
(RLM), Cli = 33 µL/min/mg (HLM) and kinetic solubility = 65 mg/L and 73, R1 = Et, R2 = H; pEC50 = 6.1, 
Cli < 19 µL/min/mg (RLM), Cli <  12 µL/min/mg (HLM) and kinetic solubility = 107 mg/L. Both compound 
pharmacokinetics were studied in vivo and showed improved oral bioavailability in the rat compared 
to previous analogues (R1 = Me, F = 15%; R1 = Et, F = 43%). The ethyl compound was progressed 
further and found to have low CNS penetration (brain to plasma ratio = 0.05). However despite the 
poor CNS permeability, it did show effects in a rat in vivo electrophysiology assay, increasing the 
amplitude of evoked activity at a dose of 0.3 mg/kg (IV). The crystal structure of 73 (R1 = Et, R2 = H) 
bound to the S1S2 LBD of hGluA2i was obtained and con-firmed the initial designed hypothesis (PDB 
code 3O6H, Fig. 24). The authors conclude by saying that at the time of publication the advanced 
compound was under detailed investigation and further results will be published at a later date (Fig. 
22). 
 
Fig. (22). Key compounds in the optimization of screening hit 68 published by Organon. 
 
Fig. (23). Biostructure of lead 71 (R = NMe2, n = 2) bound to the S1S2 LBD of hGluA2i (PDB code 3O29, 
2.02 Å resolution). 
 
Fig. (24). X-ray structure of 73 (R1 = Et, R2 = H) in complex with the S1S2 LBD of hGluA2i (PDB code 
3O6H, 2.1 Å resolution). 
 
Fig. (25). Advanced compounds from Organon and comparison with similar templates from other 
groups. 
In the final publication,[127] further evolution of the template to structurally diverse scaffolds was 
explored using a hybridisation strategy (Fig. 25). Structural components of other reported AMPA 
modulators were combined with key elements of the newly discovered scaffold, in order to identify a 
back-up series. The work resulted in the identification of compound 77. Examination of available X-
ray structures suggested that 74 (hGluA1 pEC50 = 6.4, solubility = 20 mg/L) had the potential to be 
hybridised with the previously reported Lilly compound (LY451646, 48) by replacing the cyanophenyl 
group with the pyrazole moiety of 74 to give 75. The results were initially encouraging with 75 having 
the desired in vitro profile (pEC50 = 6.3, solubility = 73 mg/L and Cli < 12 µL/min/mg (rat and human)), 
combined with reasonable permeability (Caco-2) and no evidence of transporter interaction. However 
the in vivo rat profile was less than desired with high plasma clearance (49.7 mL/min/kg). It was 
hypothesized that the introducing conformation constraint might have reduced CYP-mediated 
metabolism leading to a decreased clearance.  
A second hybridisation strategy was employed to achieve the conformation restraint, incorporating 
features of a template described by GlaxoSmithKline 9[82] producing 76 (PDB code 3PMW, Fig. 26). A 
linker was introduced be-tween the indane and the pyrazole as molecular modelling suggested the 
directly linked pyrazole would not fit the binding site optimally. Derivative 76 had a very encouraging 
profile (pEC50 = 6.3, Cli = 31 µL/min/mg (RLM), 23 µL/min/mg (HLM)), improved in vivo clearance 
(21.6 mL/min/kg, rat) and excellent oral bioavailability (F% = 95). Having identified 76 as a promising 
new scaffold, the Organon group explored further the SAR around that template. Changing the 
stereochemistry of these compounds had little effect on the overall profile of the compounds. The 
pyrazole ring could be replaced by other 5-membered heterocycles including furan and pyrrole. A 
range of substituents in place of the alcohol are tolerated including hydrophobic groups such as an 
additional trifluoromethyl and polar groups such as secondary amines. Exploration of the sulfonamide 
demonstrated that a wide range of hydrophobic groups are tolerated in this position including 
aromatic groups such as methoxyphenyl and trifluoromethyl pyrazole. Compound 77 resulted from 
this exploration and it was noted that replacement of the isopropyl sulfonamide by the corresponding 
trifluoro methyl analogue gave a compound which retained much of the potency of 76 but with further 
improved metabolic stability. The profile of 77 is as follows: pEC50 = 5.6, solubility = 83 mg/L, Cli < 12 
µL/min/mg (RLM and HLM), in vivo (rat) Cl = 1.9 mL/min/kg, t1/2 = 7.4 h, F% = 100, and evidence of 
good CNS penetration. No report describing the in vivo pharmacological effects of the AMPAR 
potentiators described in these three papers has been published by Organon and it is unclear if these 
series are still being developed (Fig. 27).  
A recent publication from one of the Organon authors currently working at the University of 
Strathclyde described another hybridisation strategy,[130] in which the hydroxymethyl pyrazole used 
in the design of 77 is combined with a template related to those previously described by Cortex to 
produce hybrid 79. Only in vitro activity data is de-scribed in an electrophysiology assay with 
compounds being tested on both flip and flop isoforms of GluA2. Modulator 79 is significantly more 
potent than 74 and shows activity at both receptor subtypes. Also described in the paper are the 
sulfonamide analogue 80 and the compound in which the pyrazole is directly attached to the tricyclic 
core 81, both compounds are less potent than 79 (Fig. 28).  
WORK FROM OTHER PHARMACEUTICAL AND ACADEMIC GROUPS  
A number of groups at the universities of Liege, Copenhagen and Modena have published work 
centred around the thiadiazine template 5.[131–138] Servier also worked for many years on this 
template but have not described any new chemotypes related to this scaffold in the period covered 
by this article. This work has been comprehensively reviewed elsewhere. [139]  
Takeda have demonstrated an interest in this area of neuroscience through a significant number of 
patent applications between 2009 and 2012. [140–145] However until now no scientific publication 
reporting on their strategy and discovery of advanced AMPAR PAMS has been published. Lilly which 
had a strong interest in the area before 2010 seems to have stopped working on AMPAR PAMS, since 
no patent or scientific articles originating from them has been reported in the last 6 years. 
 Fig. (26). X-ray structure of 76 bound to the S1S2 LBD of hGluA2i (PDB code 3PMW, 2.2 Å resolution). 
 
Fig. (27). Conformationally restrained molecules published by Organon. 
 
Fig. (28). Representative structures of the AMPAR modulators claimed by Takeda. 
CONCLUSION AND FUTURE PERSPECTIVE  
The large number of publications on AMPAR potentiators within the period covers by this article 
proves that it remains a fertile area of drug discovery and that interest will remain for the foreseeable 
future. It appears that the field has learnt from the failure of the early AMPAR PAMs which entered 
clinical evaluation and that more precise and defined properties are now sought. The use of SBDD has 
clearly assisted a number of projects and allowed the identification of very potent potentiators, active 
at very low doses in cognition behavioural models in vivo. Some pharmaceutical groups such as Pfizer 
and GSK have also aimed for a specific pharmacokinetic profile with the objective to achieve large TI, 
low intersubject pharmacokinetics variability and prevent the occurrence of the recognized adverse 
events associated with AMPAR modulators. We can expect a number of compounds derived from 
series described in this review to enter clinical evaluation in the next few years, thus expectation of 
positive readouts of clinical trial data continues.  
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